US 6,506,411 B2 · Anti-angiogenic compositions and methods of use

Abstract

The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and paclitaxel. Also, provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.

Claims11

Dependent claims

A composition, comprising:

(a) a compound which disrupts microtubule function;
and
(b) a non-biodegradable polymer.

Dependencies are inferred from the claim text.

Facts

Application

09/294,458Filed 19 Apr 1999 · continuation

Priority

WO PCT/CA94/0037319 Jul 1994

Published

US 2002/0164377 A17 Nov 2002

Granted

14 Jan 2003

Term ends

Not estimatedThe source records don’t support an estimate.

Classification72 codes

A61K 9/14
Medicinal preparations characterised by special physical form: particulate form, e.g. powders, Processes for size reducing of pure drugs or the…
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 9/0048
Galenical forms characterised by the site of application: eye, e.g. artificial tears
A61K 9/0051
Eye, e.g. artificial tears: ocular inserts or implants

Family

Application08/094,536Parent of this continuation-in-part · filed 19 Jul 1993

Application08/417,160Parent of this division · filed 3 Apr 1995

Application08/480,260Parent of this continuation · filed 7 Jun 1995

US 2002/0164377 A1Pre-grant publication · published 7 Nov 2002

Application08/480,260Parent of this division

Application08/417,160Parent of this continuation-in-part

US 6,506,411 B2This patent

From the US filing history. Foreign family members aren’t listed.

Abstract

Facts

Application

09/294,458Filed 19 Apr 1999 · continuation

Priority

WO PCT/CA94/0037319 Jul 1994

Published

US 2002/0164377 A17 Nov 2002

Granted

14 Jan 2003

Term ends

Not estimatedThe source records don’t support an estimate.

Classification72 codes

A61K 9/14
Medicinal preparations characterised by special physical form: particulate form, e.g. powders, Processes for size reducing of pure drugs or the…
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 9/0048
Galenical forms characterised by the site of application: eye, e.g. artificial tears
A61K 9/0051
Eye, e.g. artificial tears: ocular inserts or implants

Family

Application08/094,536Parent of this continuation-in-part · filed 19 Jul 1993

Application08/417,160Parent of this division · filed 3 Apr 1995

Application08/480,260Parent of this continuation · filed 7 Jun 1995

US 2002/0164377 A1Pre-grant publication · published 7 Nov 2002

Application08/480,260Parent of this division

Application08/417,160Parent of this continuation-in-part

US 6,506,411 B2This patent

From the US filing history. Foreign family members aren’t listed.

Anti-angiogenic compositions and methods of use

Life of this patent

Abstract

Claims11

Anti-angiogenic compositions and methods of use

Life of this patent

Abstract

Claims11